ISRG vs. NTRA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ISRG and NTRA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ISRG | NTRA |
|---|---|---|
| Company Name | Intuitive Surgical, Inc. | Natera, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 196.99 billion USD | 28.59 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | June 16, 2000 | July 1, 2015 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ISRG and NTRA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ISRG | NTRA |
|---|---|---|
| 5-Day Price Return | -4.63% | -1.14% |
| 13-Week Price Return | 14.42% | 25.31% |
| 26-Week Price Return | -2.56% | 34.15% |
| 52-Week Price Return | 2.39% | 26.91% |
| Month-to-Date Return | 2.85% | 2.69% |
| Year-to-Date Return | 5.28% | 29.05% |
| 10-Day Avg. Volume | 2.18M | 1.64M |
| 3-Month Avg. Volume | 2.35M | 1.30M |
| 3-Month Volatility | 39.64% | 33.50% |
| Beta | 1.67 | 1.64 |
Profitability
Return on Equity (TTM)
ISRG
16.06%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
In the upper quartile for the Health Care Equipment & Supplies industry, ISRG’s Return on Equity of 16.06% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
NTRA
-25.07%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
NTRA has a negative Return on Equity of -25.07%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ISRG
28.58%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
ISRG’s Net Profit Margin of 28.58% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
NTRA
-14.61%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
NTRA has a negative Net Profit Margin of -14.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
ISRG
29.30%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
An Operating Profit Margin of 29.30% places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
NTRA
-16.62%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
NTRA has a negative Operating Profit Margin of -16.62%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ISRG | NTRA |
|---|---|---|
| Return on Equity (TTM) | 16.06% | -25.07% |
| Return on Assets (TTM) | 14.18% | -17.74% |
| Net Profit Margin (TTM) | 28.58% | -14.61% |
| Operating Profit Margin (TTM) | 29.30% | -16.62% |
| Gross Profit Margin (TTM) | 66.38% | 63.66% |
Financial Strength
Current Ratio (MRQ)
ISRG
4.97
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
ISRG’s Current Ratio of 4.97 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
NTRA
3.27
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
NTRA’s Current Ratio of 3.27 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ISRG
0.00
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, ISRG’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
NTRA
0.06
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
NTRA’s Debt-to-Equity Ratio of 0.06 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ISRG
--
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
Interest Coverage Ratio data for ISRG is currently unavailable.
NTRA
-57.80
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
NTRA has a negative Interest Coverage Ratio of -57.80. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ISRG | NTRA |
|---|---|---|
| Current Ratio (MRQ) | 4.97 | 3.27 |
| Quick Ratio (MRQ) | 4.20 | 3.01 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.06 |
| Interest Coverage Ratio (TTM) | -- | -57.80 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ISRG | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ISRG
70.92
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
At 70.92, ISRG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
NTRA
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for NTRA is currently unavailable.
Price-to-Sales Ratio (TTM)
ISRG
20.27
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
With a P/S Ratio of 20.27, ISRG trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
NTRA
13.53
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
NTRA’s P/S Ratio of 13.53 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ISRG
9.41
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
ISRG’s P/B Ratio of 9.41 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
NTRA
17.64
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
NTRA’s P/B Ratio of 17.64 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ISRG | NTRA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 70.92 | -- |
| Price-to-Sales Ratio (TTM) | 20.27 | 13.53 |
| Price-to-Book Ratio (MRQ) | 9.41 | 17.64 |
| Price-to-Free Cash Flow Ratio (TTM) | 85.77 | 306.11 |